Tralokinumab Vaccine Response Time
ClinicalTrials.gov NCT03562377
Research payments
$1,870,435
Through program year 2019, $1,870,435 in research payments was reported against Tralokinumab Vaccine Response Time, across 277 payments, paid by LEO Pharma AS.
- Paid by
- LEO Pharma AS
- ClinicalTrials.gov
- NCT03562377
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | Research | $1,870,435 | 277 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Barbara Baxter Dallas, TX Named on 58 payments
- David Bernstein Cincinnati, OH Named on 28 payments
- Debra Breneman Cincinnati, OH Named on 16 payments
- David Stoll Beverly Hills, CA Named on 11 payments
- Carl Thornblade Missoula, MT Named on 10 payments
- Afshin Farzadmehr Los Angeles, CA Named on 9 payments
- Manuel Sanchez Hialeah, FL Named on 9 payments
- Christopher Smith Corning, NY Named on 9 payments
- Paul Shapero Bangor, ME Named on 8 payments
- Delilah Alonso South Miami, FL Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.